

25 August 2025

ASX Announcement

Nasodine COVID-19 Patent Granted in Australia

Firebrick Pharma Limited (ASX:FRE) (**Company** or **Firebrick**) is pleased to announce that the Company's patent covering the use of Nasodine® Nasal Spray (Nasodine) in COVID-19 had been granted in Australia. The patent dated is titled: *"Prevention of infection by highly pathogenic viruses using topical application of povidone-iodine on mucous membranes."*

The patent protects the use of Nasodine® Nasal Spray ("Nasodine") or any other intranasal povidone-iodine (PVP-I) preparations as a method of reducing the viral load of SARS-CoV-2 in the nose. Granted claims also cover pre-exposure prophylaxis (preventative use prior to exposure) against SARS-CoV-2.

"This patent covers the use of nasal PVP-I for reducing the viral load and thereby shedding of the COVID virus. However, it also covers using it as a way to protect a person from getting infected, which covers potentially a wide range of usage situations," said Firebrick Executive Chairman, Dr Peter Molloy. "Combined with the broad approved claims in our common cold patent, we believe we have strong commercial protection for Nasodine."

In addition to Australia, this patent is now accepted or granted in both US and Europe, as well as South Africa and Mexico. The patent expires in 2040 in Australia and all other markets where it is granted. In Australia, this new standard patent augments (and ultimately replaces) Firebrick's innovation patent with the same title (No. 2019100465) that expires 10 June 2028.

This announcement was authorised for release by Dr Peter Molloy, Executive Chairman, Firebrick Pharma Limited.

- ENDS -

About Firebrick (ASX:FRE)

Firebrick Pharma is a pharmaceutical innovator that is developing and commercialising novel formulations and uses of povidone-iodine (PVP-I). The Company has developed and is now commercialising Nasodine® Nasal Spray (0.5% PVP-I) and has several other products in development. Firebrick has already introduced Nasodine Nasal Spray into the United States, Singapore and Fiji & South Pacific, with a launch in the Philippines expected in 2026.

Media enquiries:

Heidi Cuthbert

+61 411 272 366

heidi.cuthbert@multiplier.com.au

Investor enquiries:

Investors@firebrickpharma.com